Companies / Elicio Therapeutics, Inc. / Activity
Activity — Elicio Therapeutics, Inc.
8 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | Connelly Robert CEO | Grant | Common Stock | $0 | +74K +156.70% | 120,570 0.63% of shares | low |
| Feb 2, 2026 | Shah Preetam Executive | Grant | Common Stock | $0 | +24K | 24,000 0.13% of shares | low |
| Feb 2, 2026 | Haqq Christopher Executive | Grant | Common Stock | $0 | +25K +79.42% | 57,381 0.30% of shares | low |
| Feb 2, 2026 | DeMuth Peter Executive | Grant | Common Stock | $0 | +21K +2799.46% | 21,543 0.11% of shares | low |
| Feb 2, 2026 | Connelly Robert CEO | Grant | Stock Option (Right to Buy) | — | +147K | 147,200 0.77% of shares | low |
| Feb 2, 2026 | Shah Preetam Executive | Grant | Stock Option (Right to Buy) | — | +48K | 47,900 0.25% of shares | low |
| Feb 2, 2026 | Haqq Christopher Executive | Grant | Stock Option (Right to Buy) | — | +51K | 50,900 0.27% of shares | low |
| Feb 2, 2026 | DeMuth Peter Executive | Grant | Stock Option (Right to Buy) | — | +42K | 41,600 0.22% of shares | low |